+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Depression Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030- Product Image
Depression Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030- Product Image
New

Depression Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • PDF Icon

    Report

  • 182 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5950455
Free Webex Call
10% Free customization
Description Jump to:

Branded Drugs is the fastest growing segment, North America is the largest market globally

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Depression Drugs Market will grow from USD 18.46 Billion in 2024 to USD 21.79 Billion by 2030 at a 2.80% CAGR. The global depression drugs market encompasses pharmaceutical agents specifically developed to treat major depressive disorder and related mental health conditions, functioning primarily by modulating neurotransmitter activity in the brain. Key drivers bolstering this market's expansion include the escalating global prevalence of mental health disorders, a growing public awareness of these conditions leading to increased diagnoses, and continuous advancements in pharmaceutical research and development introducing novel therapeutic options.

Key Market Drivers

The increasing prevalence of depressive disorders fundamentally propels the global depression drugs market by expanding the patient population requiring pharmacological interventions. These conditions represent a substantial portion of the global disease burden, necessitating a continuous supply of effective treatments. According to the World Health Organization, in September 2025, in their 'World Mental Health Today: Latest Data' and 'Mental Health Atlas 2024' reports, over one billion people worldwide are living with mental health disorders, with anxiety and depressive disorders collectively constituting more than two-thirds of all cases.

Key Market Challenges

A significant challenge impeding the sustained growth of the global depression drugs market is the limited accessibility of mental healthcare services and essential medications, particularly within emerging economies. These regions frequently contend with inadequate healthcare infrastructure and insufficient numbers of mental health professionals. This accessibility gap directly restricts patient reach and the uptake of necessary pharmacological interventions, thereby hindering overall market expansion.

Key Market Trends

The emergence of psychedelic-assisted treatment modalities represents a significant shift in the therapeutic landscape for depression, offering novel mechanisms of action beyond conventional monoaminergic approaches. These therapies, often involving compounds like psilocybin and lysergic acid diethylamide (LSD) alongside psychological support, are demonstrating promising efficacy, particularly for treatment-resistant depression. For instance, Compass Pathways announced in June 2025 that its COMP360 psilocybin achieved the primary endpoint in a Phase 3 trial for treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depressive symptoms after six weeks.

Key Market Players Profiled:

  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Eli Lilly and Company
  • AstraZeneca plc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Co., Ltd.
  • AbbVie, Inc.
  • Johnson & Johnson

Report Scope:

In this report, the Global Depression Drugs Market has been segmented into the following categories:

By Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

By Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

By Drug Type:

  • Generic Drugs
  • Branded Drugs

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Depression Drugs Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:
  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Depression Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Others)
5.2.2. By Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others)
5.2.3. By Drug Type (Generic Drugs, Branded Drugs)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Depression Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Disorder Type
6.2.3. By Drug Type
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Depression Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Disorder Type
6.3.1.2.3. By Drug Type
6.3.2. Canada Depression Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Disorder Type
6.3.2.2.3. By Drug Type
6.3.3. Mexico Depression Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Disorder Type
6.3.3.2.3. By Drug Type
7. Europe Depression Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Disorder Type
7.2.3. By Drug Type
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Depression Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Disorder Type
7.3.1.2.3. By Drug Type
7.3.2. France Depression Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Disorder Type
7.3.2.2.3. By Drug Type
7.3.3. United Kingdom Depression Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Disorder Type
7.3.3.2.3. By Drug Type
7.3.4. Italy Depression Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Disorder Type
7.3.4.2.3. By Drug Type
7.3.5. Spain Depression Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Disorder Type
7.3.5.2.3. By Drug Type
8. Asia Pacific Depression Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Disorder Type
8.2.3. By Drug Type
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Depression Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Disorder Type
8.3.1.2.3. By Drug Type
8.3.2. India Depression Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Disorder Type
8.3.2.2.3. By Drug Type
8.3.3. Japan Depression Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Disorder Type
8.3.3.2.3. By Drug Type
8.3.4. South Korea Depression Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Disorder Type
8.3.4.2.3. By Drug Type
8.3.5. Australia Depression Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Disorder Type
8.3.5.2.3. By Drug Type
9. Middle East & Africa Depression Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Disorder Type
9.2.3. By Drug Type
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Depression Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Disorder Type
9.3.1.2.3. By Drug Type
9.3.2. UAE Depression Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Disorder Type
9.3.2.2.3. By Drug Type
9.3.3. South Africa Depression Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Disorder Type
9.3.3.2.3. By Drug Type
10. South America Depression Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Disorder Type
10.2.3. By Drug Type
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Depression Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Disorder Type
10.3.1.2.3. By Drug Type
10.3.2. Colombia Depression Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Disorder Type
10.3.2.2.3. By Drug Type
10.3.3. Argentina Depression Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Disorder Type
10.3.3.2.3. By Drug Type
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Depression Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Otsuka Holdings Co., Ltd.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer, Inc.
15.3. Eli Lilly and Company
15.4. AstraZeneca plc.
15.5. Novartis AG
15.6. Bristol-Myers Squibb Company
15.7. GlaxoSmithKline plc.
15.8. Takeda Pharmaceutical Co., Ltd.
15.9. AbbVie, Inc.
15.10. Johnson & Johnson
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Eli Lilly and Company
  • AstraZeneca plc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Co., Ltd.
  • AbbVie, Inc.
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages182
PublishedNovember 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 18.46 Billion
Forecasted Market Value ( USD ) by 2030 $ 21.79 Billion
Compound Annual Growth Rate2.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Depression Drugs Market - Global Strategic Business Report - Product Image

Depression Drugs Market - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Depression Drugs Market 2025-2033 - Product Image

Depression Drugs Market 2025-2033

  • Report
  • 148 Pages
  • Global
From
Treatment Resistant Depression Drug Pipeline Analysis Report 2025 - Product Image

Treatment Resistant Depression Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Postpartum Depression Drugs Market - Global Strategic Business Report - Product Image

Postpartum Depression Drugs Market - Global Strategic Business Report

  • Report
  • 479 Pages
  • Global
From
Anxiety Disorders and Depression Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Anxiety Disorders and Depression Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.